Abediterol/mometasone

Drug Profile

Abediterol/mometasone

Alternative Names: Abediterol/ICS; Abediterol/mometasone furoate; LAS 410171; LAS-100977/corticosteroid; LAS100977/ICS; Mometasone furoate/abediterol; Mometasone/abediterol; OD LABA2

Latest Information Update: 27 Jul 2015

Price : $50

At a glance

  • Originator Almirall S.A.
  • Class Antiasthmatics; Bronchodilators; Corticosteroids; Glucocorticoids; Pregnadienediols
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 27 Jul 2015 Phase-II development is ongoing for Asthma in Europe
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top